皮眼科解决方案可减少儿科患者近视的进展:随机,双盲多中心II期APPLE研究
Audrey Chia1, Cheryl Ngo2, Nozhat Choudry3
1Singapore National Eye Centre, Singapore, Singapore.
概括
低剂量阿特罗宾眼液的0.005%和0.01%有效地减缓了儿童近视的进展. 最低剂量 (0.0025%) 没有影响,但所有阿特罗宾配方均安全且耐受良好.
科学领域:
- 眼科医生 眼科 眼科
- 儿科医学 儿科医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 近视或近视是儿童日益严重的公共卫生问题.
- 需要有效的干预措施来减缓近视的进展,并预防相关的眼睛健康并发症.
研究的目的:
- 为了评估低剂量氨酸在治疗儿科近视时的剂量反应关系.
- 与安慰剂相比,评估不同度 (0.0025%,0.005%,0.01%) 的阿特罗宾的安全性和有效性.
主要方法:
- 一个II期,随机,双面膜,安慰剂对照试验,涉及99名儿童 (6-11岁) 轻度至中度近视.
- 参与者在12个月内每天晚上在每只眼睛中接受一滴阿特罗宾或安慰剂.
- 主要结局是球体等价值 (SE) 的变化;次要结局包括轴长 (AL) 和视力敏度.
主要成果:
- 与安慰剂相比,Atropine 0.005%和0.01%显著降低了近视进展 (SE变化分别为-0.33 D和-0.39 D) (-0.55 D).
- 观察到0.005% (-0.09毫米) 和0.01% (-0.10毫米) 的热素与安慰剂相比,轴长度延长的显著差异.
- 没有注意到近视敏度的显著变化;常见的副作用包括轻微的和视力模糊,对瞳孔大小或住宿的影响最小.
结论:
- 低剂量的0.005%和0.01%的阿特罗宾在减缓儿童近视进展方面表现出有效性.
- 在这项研究中,0.0025%的阿特罗宾剂量没有有效.
- 所有测试的阿特罗宾度被发现是安全的,并被儿科参与者很好地容忍.
相关概念视频
Open Angle Glaucoma: Treatment
480
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
480
Angle Closure Glaucoma: Treatment
563
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
563
Direct-Acting Cholinergic Agonists: Therapeutic Uses
791
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
791
Glaucoma: Overview
621
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
621
Focusing of Light in the Eye
2.9K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.9K
Cholinergic Antagonists: Pharmacokinetics
516
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
516


